Alison Merikangas

Dr. Alison Merikangas


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
AMAlison Merikangas
Alison Merikangas
MSMatthew Shelly
Matthew Shelly
AKAlexys Knighton
Alexys Knighton
NKNicholas Kotler
Nicholas Kotler
NTNicole Tanenbaum
Nicole Tanenbaum
LALaura Almasy
Laura Almasy
Schizophrenia is a severe, complex mental disorder characterized by a combination of positive symptoms, negative symptoms, and impaired cognitive function. Schizophrenia is highly heritable (~80%) with multifactorial etiology and complex polygenic genetic architecture. Despite the large number of genetic variants associated with schizophrenia, few causal variants have been established. Gaining insight into the mechanistic influences of these genetic variants may facilitate our ability to apply these findings to prevention and treatment. Though there have been more than 300 studies of gene expression in schizophrenia over the past 15 years, none of the studies have yielded consistent evidence for specific genes that contribute to schizophrenia risk. The aim of this work is to conduct a systematic review and synthesis of case–control studies of genome-wide gene expression in schizophrenia. Comprehensive literature searches were completed in PubMed, EmBase, and Web of Science, and after a systematic review of the studies, data were extracted from those that met the following inclusion criteria: human case–control studies comparing the genome-wide transcriptome of individuals diagnosed with schizophrenia to healthy controls published between January 1, 2000 and June 30, 2020 in the English language. Genes differentially expressed in cases were extracted from these studies, and overlapping genes were compared to previous research findings from the genome-wide association, structural variation, and tissue-expression studies. The transcriptome-wide analysis identified different genes than those previously reported in genome-wide association, exome sequencing, and structural variation studies of schizophrenia. Only one gene, GBP2, was replicated in five studies. Previous work has shown that this gene may play a role in immune function in the etiology of schizophrenia, which in turn could have implications for risk profiling, prevention, and treatment. This review highlights the methodological inconsistencies that impede valid meta-analyses and synthesis across studies. Standardization of the use of covariates, gene nomenclature, and methods for reporting results could enhance our understanding of the potential mechanisms through which genes exert their influence on the etiology of schizophrenia. Although these results are promising, collaborative efforts with harmonization of methodology will facilitate the identification of the role of genes underlying schizophrenia.

29 April 2020 in Genes, Brain and Behavior
Verified
Journal Article
Open access
PDF file
AMAlison Merikangas
Alison Merikangas
LALaura Almasy
Laura Almasy
Many neuropsychiatric disorders exhibit differences in prevalence, age of onset, symptoms or course of illness between males and females. For the most part, the origins of these differences are not well understood. In this article, we provide an overview of sex differences in psychiatric disorders including autism spectrum disorder (ASD), attention deficit/hyperactivity disorder (ADHD), anxiety, depression, alcohol and substance abuse, schizophrenia, eating disorders and risk of suicide. We discuss both genetic and nongenetic mechanisms that have been hypothesized to underlie these differences, including ascertainment bias, environmental stressors, X‐ or Y‐linked risk loci, and differential liability thresholds in males and females. We then review the use of twin, family and genome‐wide association approaches to study potential genetic mechanisms of sex differences and the extent to which these designs have been employed in studies of psychiatric disorders. We describe the utility of genetic epidemiologic study designs, including classical twin and family studies, large‐scale studies of population registries, derived recurrence risks, and molecular genetic analyses of genome‐wide variation that may enhance our understanding sex differences in neuropsychiatric disorders.

6 July 2020 in Biological Psychiatry
Verified
Journal Article
Open access
RKRachel L. Kember
Rachel L. Kember
AMAlison Merikangas
Alison Merikangas
SVShefali S. Verma
Shefali S. Verma
AVAnurag Verma
Anurag Verma
RJRenae Judy
Renae Judy
MBMaja Bućan
Maja Bućan
Prediction of disease risk is a key component of precision medicine. Common traits such as psychiatric disorders have a complex polygenic architecture making the identification of a single risk predictor difficult. Polygenic risk scores (PRS) denoting the sum of an individual’s genetic liability for a disorder are a promising biomarker for psychiatric disorders, but require evaluation in a clinical setting. We develop PRS for six psychiatric disorders (schizophrenia, bipolar disorder, major depressive disorder, cross disorder, attention-deficit/hyperactivity disorder, anorexia nervosa) and 17 non-psychiatric traits in over 10,000 individuals from the Penn Medicine Biobank with accompanying electronic health records (EHR). We perform phenome-wide association analyses to test their association across disease categories. Four of the six psychiatric PRS were associated with their primary phenotypes (odds ratios between 1.2–1.6). Cross-trait associations were identified both within the psychiatric domain and across trait domains. PRS for coronary artery disease and years of education were significantly associated with psychiatric disorders, largely driven by an association with tobacco use disorder. We demonstrate that the genetic architecture of EHR-derived psychiatric diagnoses is similar to ascertained research cohorts from large consortia. Psychiatric PRS are moderately associated with psychiatric diagnoses, but are not yet clinically predictive in naïve patients. Cross-trait associations for these PRS suggest a broader effect of genetic liability beyond traditional diagnostic boundaries. As identification of genetic markers increases, including PRS alongside other clinical risk factors may enhance prediction of psychiatric disorders and associated conditions in clinical registries.

22 September 2023 in Genes, Brain and Behavior
Verified
Journal Article
Open access
AAArpana Agrawal
Arpana Agrawal
SBSarah J. Brislin
Sarah J. Brislin
KBKathleen K. Bucholz
Kathleen K. Bucholz
DDDanielle Dick
Danielle Dick
RHRonald P. Hart
Ronald P. Hart
BPBernice Porjesz
Bernice Porjesz
Alcohol use disorders (AUD) are commonly occurring, heritable and polygenic disorders with etiological origins in the brain and the environment. To outline the causes and consequences of alcohol‐related milestones, including AUD, and their related psychiatric comorbidities, the Collaborative Study on the Genetics of Alcoholism (COGA) was launched in 1989 with a gene‐brain‐behavior framework. COGA is a family based, diverse (~25% self‐identified African American, ~52% female) sample, including data on 17,878 individuals, ages 7–97 years, in 2246 families of which a proportion are densely affected for AUD. All participants responded to questionnaires (e.g., personality) and the Semi‐Structured Assessment for the Genetics of Alcoholism (SSAGA) which gathers information on psychiatric diagnoses, conditions and related behaviors (e.g., parental monitoring). In addition, 9871 individuals have brain function data from electroencephalogram (EEG) recordings while 12,009 individuals have been genotyped on genome‐wide association study (GWAS) arrays. A series of functional genomics studies examine the specific cellular and molecular mechanisms underlying AUD. This overview provides the framework for the development of COGA as a scientific resource in the past three decades, with individual reviews providing in‐depth descriptions of data on and discoveries from behavioral and clinical, brain function, genetic and functional genomics data. The value of COGA also resides in its data sharing policies, its efforts to communicate scientific findings to the broader community via a project website and its potential to nurture early career investigators and to generate independent research that has broadened the impact of gene‐brain‐behavior research into AUD.

30 June 2023 in Genes, Brain and Behavior
Verified
Journal Article
Open access
EJEmma Johnson
Emma Johnson
JSJessica E. Salvatore
Jessica E. Salvatore
DLDongbing Lai
Dongbing Lai
AMAlison Merikangas
Alison Merikangas
JNJohn I. Nurnberger
John I. Nurnberger
AAArpana Agrawal
Arpana Agrawal
This review describes the genetic approaches and results from the family‐based Collaborative Study on the Genetics of Alcoholism (COGA). COGA was designed during the linkage era to identify genes affecting the risk for alcohol use disorder (AUD) and related problems, and was among the first AUD‐focused studies to subsequently adopt a genome‐wide association (GWAS) approach. COGA's family‐based structure, multimodal assessment with gold‐standard clinical and neurophysiological data, and the availability of prospective longitudinal phenotyping continues to provide insights into the etiology of AUD and related disorders. These include investigations of genetic risk and trajectories of substance use and use disorders, phenome‐wide association studies of loci of interest, and investigations of pleiotropy, social genomics, genetic nurture, and within‐family comparisons. COGA is one of the few AUD genetics projects that includes a substantial number of participants of African ancestry. The sharing of data and biospecimens has been a cornerstone of the COGA project, and COGA is a key contributor to large‐scale GWAS consortia. COGA's wealth of publicly available genetic and extensive phenotyping data continues to provide a unique and adaptable resource for our understanding of the genetic etiology of AUD and related traits.

5 October 2021 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
EHEmily E. Hartwell
Emily E. Hartwell
AMAlison Merikangas
Alison Merikangas
SVShefali Setia Verma
Shefali Setia Verma
MRMarylyn Ritchie
Marylyn Ritchie
RCRegeneron Genetics Center
Regeneron Genetics Center
RKRachel L. Kember
Rachel L. Kember